ImmunoGen Announces Departure of Chief Development Officer
August 09 2016 - 8:30AM
Business Wire
ImmunoGen, Inc. (Nasdaq: IMGN), a
leader in the expanding field of antibody-drug conjugates (ADCs)
for the treatment of cancer, today announced that Charles Morris,
MBChB, MRCP, Executive Vice President and Chief Development
Officer, is leaving the Company effective September 2 to pursue an
opportunity closer to his primary residence in Pennsylvania.
“Charlie has made a significant contribution to ImmunoGen over
these past four years,” said Mark Enyedy, President and CEO. “He
played a key role in building a strong development organization,
including an experienced team led by our Chief Medical Officer and
Vice President, Anna Berkenblit, MD, and our Vice President,
Regulatory Affairs, Theresa Wingrove, PhD. Anna and Theresa
will now report directly to me, as we advance our pipeline and
initiate the Phase 3 study of mirvetuximab soravtansine before the
end of the year. We wish Charlie the very best in his new
role.”
“ImmunoGen is successfully implementing a speed-to-market
strategy for our lead product candidate, mirvetuximab soravtansine,
is accelerating a strong pipeline behind it, and continues to drive
significant ADC innovations,” commented Dr. Morris. “I am proud of
what we have accomplished with our portfolio and look forward to
ImmunoGen’s continued success, as this talented development team
advances these exciting ADC programs to benefit patients with
cancer.”
About ImmunoGen, Inc.
ImmunoGen is a clinical-stage biotechnology company that
develops targeted cancer therapeutics using its proprietary ADC
technology. ImmunoGen’s lead product candidate, mirvetuximab
soravtansine, is advancing to Phase 3 testing for FRα-positive
platinum-resistant ovarian cancer, with a strong pipeline
progressing behind it. ImmunoGen’s ADC technology is used in
Roche's marketed product, Kadcyla®, and in programs in development
by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi
and Takeda.
Kadcyla® is a registered trademark of Genentech, a member of the
Roche Group.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160809005203/en/
For Investors:ImmunoGen, Inc.Carol Hausner,
781-895-0600info@immunogen.comorFor Media:Michael Lampe,
484-575-5040michael@scientpr.com
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Mar 2024 to Apr 2024
ImmunoGen (NASDAQ:IMGN)
Historical Stock Chart
From Apr 2023 to Apr 2024